Replimune Group Inc (REPL): Next-Year EPS Estimate 31.72%
As of 2026-07-31, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 31.72%. Featured in our EPS revision report on 2026-04-22.
On 2026-07-31, analyst consensus for REPL's next-year EPS growth shifted from 27.41% to 31.72% — a positive change of 4.31 percentage points. Current-year growth is projected at 28.20%.
What's Driving This
No EPS estimate upgrade appears in the data; the latest revision actually lowered next-year growth from 41.73% to 36.15%, with the current estimate at 31.72%. Recent headlines are dominated by the FDA’s second complete response letter for RP1 and sharp share declines. No specific catalyst for rising share price is evident in the provided information.
Generated 2026-07-31 from news as of 2026-07-31
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 31.72%
- EPS growth this year
- 28.20%
- EPS next quarter (est)
- -$0.64
- Last price
- $11.20
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-31 | 31.72% | 28.20% | -$0.64 | $11.20 |
| 2026-07-30 | 27.41% | 30.77% | -$0.61 | $5.40 |
| 2026-07-29 | 27.41% | 30.77% | -$0.61 | $5.41 |
| 2026-07-28 | 27.41% | 30.77% | -$0.61 | $5.35 |
| 2026-07-27 | 27.41% | 30.77% | -$0.61 | $8.63 |
| 2026-07-26 | 27.41% | 30.77% | -$0.61 | $9.70 |
| 2026-07-24 | 27.41% | 30.77% | -$0.61 | $9.70 |
| 2026-07-23 | 27.41% | 30.77% | -$0.61 | $10.46 |
| 2026-07-22 | 32.27% | 30.77% | -$0.61 | $10.75 |
| 2026-07-21 | 36.80% | 35.13% | -$0.63 | $11.00 |
| 2026-07-20 | 36.80% | 35.13% | -$0.63 | $10.51 |
| 2026-07-19 | 36.80% | 35.13% | -$0.63 | $10.23 |
| 2026-07-17 | 36.80% | 35.13% | -$0.63 | $10.23 |
| 2026-07-16 | 36.80% | 35.13% | -$0.63 | $9.52 |
| 2026-07-15 | 36.80% | 35.13% | -$0.63 | $9.68 |
| 2026-07-14 | 36.80% | 35.13% | -$0.63 | $9.87 |
| 2026-07-13 | 36.80% | 35.13% | -$0.63 | $9.94 |
| 2026-07-12 | 36.80% | 35.13% | -$0.63 | $10.99 |
| 2026-07-09 | 36.80% | 35.13% | -$0.63 | $11.11 |
| 2026-07-08 | 36.80% | 35.13% | -$0.63 | $11.12 |
| 2026-07-07 | 36.80% | 35.13% | -$0.63 | $11.51 |
| 2026-07-06 | 36.01% | 35.93% | -$0.63 | $11.47 |
| 2026-07-05 | 36.01% | 35.93% | -$0.63 | $11.58 |
| 2026-07-02 | 36.01% | 35.93% | -$0.63 | $11.58 |
| 2026-07-01 | 36.01% | 35.93% | -$0.63 | $11.22 |
| 2026-06-30 | 36.01% | 35.93% | -$0.63 | $11.07 |
| 2026-06-29 | 36.15% | 44.58% | -$0.63 | $11.20 |
| 2026-06-28 | 41.73% | -1.87% | -$0.66 | $11.63 |
| 2026-06-25 | 44.44% | -5.96% | -$0.71 | $11.13 |
| 2026-06-24 | 44.44% | -5.96% | -$0.71 | $11.27 |
Reports Featuring REPL
Recent News
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.Barrons.com
- Replimune melanoma therapy rejected by FDA, shares plungeProactive
- FDA issues complete response letter to Replimunes RP1 for melanomaPharmaceutical Technology
- Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgradedInvesting.com
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
Screen Performance
Aggregate stats across all 1903 tickers our top-EPS-revision screen has flagged over the past 121 days.
- Median return since detection
- +1.2%
- % of tickers in the green
- 52%
- Median return on winners
- +18.8%
- Large revisions captured
- 1198
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Replimune Group Inc's next-year EPS growth estimate?▾
As of 2026-07-31, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 31.72%, based on analyst consensus.
When was the latest EPS estimate revision for REPL?▾
The most recent revision occurred on 2026-07-31, when analysts adjusted the next-year EPS growth estimate from 27.41% to 31.72%.
What sector and industry does Replimune Group Inc belong to?▾
Replimune Group Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. REPL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Replimune Group Inc (REPL) appears here because it was detected by our daily top-EPS-revision-performer screen.